Bioretec's RemeOs™ Trauma Screw Granted European Marketing Authorization: Latest Developments

Friday, June 28, 2024

Bioretec Ltd., a leader in bioresorbable orthopedic implants, has received an update on its European CE mark market authorization application for the RemeOs™ trauma screw from the Notified Body (Dekra).

Initial estimates suggested CE mark approval by the end of Q2 2024, but the process has experienced delays.

The expert panel evaluation, originally slated for a maximum of 60 days, has concluded, marking a significant milestone.

Bioretec is now working diligently to complete the remaining steps with the Notified Body to finalize the authorization process.

Their products, such as the RemeOs™ trauma screw, aim to improve patient outcomes by combining innovative materials science with advanced medical technology.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress